Combining treatments for liver cancer before surgery
Part of Cancer, Digestive system clinical trials.
This study tests whether giving targeted therapy and immunotherapy at the same time or one after the other is better for shrinking liver tumors that can't be removed right now but might be removable after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of liver cancer called hepatocellular carcinoma (HCC) that is at a stage where it might be shrunk before surgery.
- You have not had any previous treatment for your liver cancer.
- Your liver tumor(s) are in one lobe of the liver, or there is a small clot in the main portal vein that can be removed with the tumor.
- Your blood counts, liver function, and kidney function are within safe ranges (like enough white blood cells, platelets, and normal bilirubin levels).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests whether giving chemotherapy, immunotherapy, and targeted drugs before surgery helps prevent liver cancer from coming back in patients with high-risk tumors. You would receive treatment to shrink the tumor before your scheduled surgery.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
This trial tests a combination of liver-directed chemotherapy (HAIC), a targeted drug (lenvatinib), and an immunotherapy (envafolimab) to see if it can shrink liver cancers that are difficult to operate on. The goal is to make these cancers removable by surgery.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.